Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2005

View Archived Issues

Antithrombotic efficacy of dual-acting MC-45308

Oxytocin receptor antagonists in the prevention of preterm labor

Renal impairment does not significantly affect the PK profile of oral naftidrofuryl

Anticoagulant and antiinflammatory effects of rhAT in healthy volunteers

Darifenacin improves quality of life of patients with overactive bladder

Recent patents cover novel treatments for cognitive disorders

Novel antiglaucoma agents jointly disclosed by Ube and Santen

Vanilloid VR1 receptor modulators emerge from recent R&D

Antiviral efficacy and pharmacokinetics of single-oral dose PA-457 reported in HIV-infected patients

Antiviral efficacy and pharmacokinetics of vicriviroc alone or in combination with other antivirals

Thiovir effective against resistant HIV-1 strains and synergistic with zidovudine

ImClone Systems and UCB enter partnership for CDP-791

Vicuron stockholders vote to approve acquisition by Pfizer

Dosing begins in phase I study of GS-9132 for HCV

Vaqta approved for children as young as 12 months of age

Pfizer completes acquisition of Bioren

Astellas reports discovery of novel reverse NCX inhibitor YM-270951

Predix begins pivotal study with PRX-00023 for generalized anxiety disorder

Akorn signs agreement for AK-1015

Alnylam awarded grant for Parkinson's research

Positive phase III results for Desilux

Migenix cleared to begin phase IIb study of MX-3253 in Canada

HuMax-CD20 enters phase II study for rheumatoid arthritis

Schering-Plough exercises rights to CNTO-148

Japanese approval for Amplatzer Septal Occluder for atrial septal occlusion

Promising preliminary results for HER-2 Protein AutoVac in breast cancer

Otsuka to launch Meptin Clickhaler in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...